{"id":"W4287958183","doi":"10.1016/j.euros.2022.06.007","title":"Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment","year":2022,"lang":"en","type":"article","venue":"European Urology Open Science","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"Janssen Pharmaceuticals; Fonds de Recherche du Québec - Santé; Ferring Pharmaceuticals; Astellas Pharma Canada; Canadian Cancer Society Research Institute; Bayer; Cancer Research Society; AbbVie; Merck; Sanofi; Bristol-Myers Squibb; Amgen","keywords":"Enzalutamide; Immunotherapy; Medicine; Immune system; Bladder cancer; Prostate cancer; Cancer research; Cancer; Androgen receptor; Oncology; Antiandrogens; In vivo; Durvalumab; Internal medicine; Immunology; Biology; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005185021,0.0001565993,0.0002448732,0.00009937718,0.0009444802,0.00006743825,0.000671383,0.000009945415,0.0007328547],"category_scores_gemma":[0.000008903316,0.0001124363,0.00004933611,0.0003868142,0.0004014612,0.0001228267,0.0002791192,0.00009672708,0.00002083204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001748328,"about_ca_system_score_gemma":0.0006393368,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002153531,"about_ca_topic_score_gemma":0.00002277436,"domain_scores_codex":[0.9985408,0.000109663,0.0001533177,0.0005528793,0.0002477613,0.0003955351],"domain_scores_gemma":[0.9992743,0.00003487501,0.00008181584,0.0004159875,0.00007379961,0.0001192706],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02909617,0.008135662,0.4289942,0.00004482834,0.00371538,0.002583893,0.02608232,0.003374443,0.1302333,0.006477129,0.01106634,0.3501964],"study_design_scores_gemma":[0.03505265,0.03476954,0.1642864,0.00001921756,0.0005651679,0.001229076,0.0009214286,0.0006250567,0.009669017,0.0001166822,0.7520691,0.0006766618],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9177434,0.001220668,0.0003113401,0.006006327,0.0005403624,0.002706395,0.000129375,0.00008528331,0.07125689],"genre_scores_gemma":[0.9904522,0.00006349325,0.0008475653,0.004596596,0.00005513379,0.0003643232,0.00001370758,0.00004144669,0.003565568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7410027,"threshold_uncertainty_score":0.8024245,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04154729608095371,"score_gpt":0.3384467890099285,"score_spread":0.2968994929289748,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}